APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatic Encephalopathy Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Hepatic Encephalopathy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025185 pages

Choose your research edition.

Industry ResearchHepatic Encephalopathy Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatic Encephalopathy Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Hepatic Encephalopathy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatic Encephalopathy Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatic Encephalopathy Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Hepatic Encephalopathy Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Hepatic Encephalopathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatic Encephalopathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatic Encephalopathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Hepatic Encephalopathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hepatic Encephalopathy Drug include Umecrine Cognition AB, Spherium Biomed S.L., Rebiotix Inc., Ocera Therapeutics, Inc., KannaLife Sciences, Inc., Horizon Pharma Plc, Cosmo Pharmaceuticals S.p.A and Alfa Wassermann S.p.A, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hepatic Encephalopathy Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatic Encephalopathy Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatic Encephalopathy Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatic Encephalopathy Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatic Encephalopathy Drug Segment by Company

Umecrine Cognition AB

Spherium Biomed S.L.

Rebiotix Inc.

Ocera Therapeutics, Inc.

KannaLife Sciences, Inc.

Horizon Pharma Plc

Cosmo Pharmaceuticals S.p.A

Alfa Wassermann S.p.A

Hepatic Encephalopathy Drug Segment by Type

GR-3027

KLS-13019

RBX-2660

SYNB-1020

Others

Hepatic Encephalopathy Drug Segment by Application

Clinic

Hospital

Others

Hepatic Encephalopathy Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hepatic Encephalopathy Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hepatic Encephalopathy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Hepatic Encephalopathy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Hepatic Encephalopathy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Hepatic Encephalopathy Drug Industry Trends Table 2. Hepatic Encephalopathy Drug Industry Drivers Table 3. Hepatic Encephalopathy Drug Industry Opportunities and Challenges Table 4. Hepatic Encephalopathy Drug Industry Restraints Table 5. Global Hepatic Encephalopathy Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Hepatic Encephalopathy Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Hepatic Encephalopathy Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Hepatic Encephalopathy Drug Sales Market Share by Manufacturers Table 9. Global Hepatic Encephalopathy Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Hepatic Encephalopathy Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Hepatic Encephalopathy Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Hepatic Encephalopathy Drug Manufacturers, Product Type & Application Table 13. Global Hepatic Encephalopathy Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Hepatic Encephalopathy Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of GR-3027 Table 17. Major Manufacturers of KLS-13019 Table 18. Major Manufacturers of RBX-2660 Table 19. Major Manufacturers of SYNB-1020 Table 20. Major Manufacturers of Others Table 21. Global Hepatic Encephalopathy Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 23. Global Hepatic Encephalopathy Drug Sales by Type (2027-2032) & (W Units) Table 24. Global Hepatic Encephalopathy Drug Sales Market Share by Type (2021-2026) Table 25. Global Hepatic Encephalopathy Drug Sales Market Share by Type (2027-2032) Table 26. Global Hepatic Encephalopathy Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 27. Global Hepatic Encephalopathy Drug Revenue by Type (2021-2026) & (W Units) Table 28. Global Hepatic Encephalopathy Drug Revenue by Type (2027-2032) & (W Units) Table 29. Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2021-2026) Table 30. Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Others Table 34. Global Hepatic Encephalopathy Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 36. Global Hepatic Encephalopathy Drug Sales by Application (2027-2032) & (W Units) Table 37. Global Hepatic Encephalopathy Drug Sales Market Share by Application (2021-2026) Table 38. Global Hepatic Encephalopathy Drug Sales Market Share by Application (2027-2032) Table 39. Global Hepatic Encephalopathy Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 40. Global Hepatic Encephalopathy Drug Revenue by Application (2021-2026) & (W Units) Table 41. Global Hepatic Encephalopathy Drug Revenue by Application (2027-2032) & (W Units) Table 42. Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2021-2026) Table 43. Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2027-2032) Table 44. Global Hepatic Encephalopathy Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Hepatic Encephalopathy Drug Sales by Region (2021-2026) & (W Units) Table 46. Global Hepatic Encephalopathy Drug Sales Market Share by Region (2021-2026) Table 47. Global Hepatic Encephalopathy Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 48. Global Hepatic Encephalopathy Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Hepatic Encephalopathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 50. North America Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 51. North America Hepatic Encephalopathy Drug Sales by Country (2027-2032) & (W Units) Table 52. Europe Hepatic Encephalopathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. Europe Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 54. Europe Hepatic Encephalopathy Drug Sales by Country (2027-2032) & (W Units) Table 55. Asia Pacific Hepatic Encephalopathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Asia Pacific Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 57. Asia Pacific Hepatic Encephalopathy Drug Sales by Country (2027-2032) & (W Units) Table 58. South America, Middle East and Africa Hepatic Encephalopathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. South America, Middle East and Africa Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 60. South America, Middle East and Africa Hepatic Encephalopathy Drug Sales by Country (2027-2032) & (W Units) Table 61. Global Hepatic Encephalopathy Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Hepatic Encephalopathy Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Hepatic Encephalopathy Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Hepatic Encephalopathy Drug Revenue Market Share by Region (2021-2026) Table 65. Global Hepatic Encephalopathy Drug Revenue Market Share by Region (2027-2032) Table 66. Umecrine Cognition AB Company Information Table 67. Umecrine Cognition AB Business Overview Table 68. Umecrine Cognition AB Hepatic Encephalopathy Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Umecrine Cognition AB Hepatic Encephalopathy Drug Product Portfolio Table 70. Umecrine Cognition AB Recent Development Table 71. Spherium Biomed S.L. Company Information Table 72. Spherium Biomed S.L. Business Overview Table 73. Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Spherium Biomed S.L. Hepatic Encephalopathy Drug Product Portfolio Table 75. Spherium Biomed S.L. Recent Development Table 76. Rebiotix Inc. Company Information Table 77. Rebiotix Inc. Business Overview Table 78. Rebiotix Inc. Hepatic Encephalopathy Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Rebiotix Inc. Hepatic Encephalopathy Drug Product Portfolio Table 80. Rebiotix Inc. Recent Development Table 81. Ocera Therapeutics, Inc. Company Information Table 82. Ocera Therapeutics, Inc. Business Overview Table 83. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product Portfolio Table 85. Ocera Therapeutics, Inc. Recent Development Table 86. KannaLife Sciences, Inc. Company Information Table 87. KannaLife Sciences, Inc. Business Overview Table 88. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product Portfolio Table 90. KannaLife Sciences, Inc. Recent Development Table 91. Horizon Pharma Plc Company Information Table 92. Horizon Pharma Plc Business Overview Table 93. Horizon Pharma Plc Hepatic Encephalopathy Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Horizon Pharma Plc Hepatic Encephalopathy Drug Product Portfolio Table 95. Horizon Pharma Plc Recent Development Table 96. Cosmo Pharmaceuticals S.p.A Company Information Table 97. Cosmo Pharmaceuticals S.p.A Business Overview Table 98. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product Portfolio Table 100. Cosmo Pharmaceuticals S.p.A Recent Development Table 101. Alfa Wassermann S.p.A Company Information Table 102. Alfa Wassermann S.p.A Business Overview Table 103. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product Portfolio Table 105. Alfa Wassermann S.p.A Recent Development Table 106. Key Raw Materials Table 107. Raw Materials Key Suppliers Table 108. Hepatic Encephalopathy Drug Distributors List Table 109. Hepatic Encephalopathy Drug Customers List Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Hepatic Encephalopathy Drug Product Image Figure 2. Global Hepatic Encephalopathy Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatic Encephalopathy Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hepatic Encephalopathy Drug Sales (2021-2032) & (W Units) Figure 5. Global Hepatic Encephalopathy Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Hepatic Encephalopathy Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. GR-3027 Image Figure 9. KLS-13019 Image Figure 10. RBX-2660 Image Figure 11. SYNB-1020 Image Figure 12. Others Image Figure 13. Global Hepatic Encephalopathy Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Hepatic Encephalopathy Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Hepatic Encephalopathy Drug Sales Market Share by Type (2021-2032) Figure 16. Global Hepatic Encephalopathy Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Hepatic Encephalopathy Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Others Image Figure 22. Global Hepatic Encephalopathy Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Hepatic Encephalopathy Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Hepatic Encephalopathy Drug Sales Market Share by Application (2021-2032) Figure 25. Global Hepatic Encephalopathy Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Hepatic Encephalopathy Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 29. North America Hepatic Encephalopathy Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Canada Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Mexico Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Hepatic Encephalopathy Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. France Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. U.K. Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Italy Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Netherlands Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Hepatic Encephalopathy Drug Sales Market Share by Country (2021-2032) Figure 42. China Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Japan Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. South Korea Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Southeast Asia Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. India Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Australia Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Hepatic Encephalopathy Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South Africa Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Saudi Arabia Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Turkey Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Argentina Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. UAE Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Egypt Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Chile Hepatic Encephalopathy Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Global Hepatic Encephalopathy Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Hepatic Encephalopathy Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Hepatic Encephalopathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Hepatic Encephalopathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Hepatic Encephalopathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Hepatic Encephalopathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Hepatic Encephalopathy Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Hepatic Encephalopathy Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • GR-3027
  • KLS-13019
  • RBX-2660
  • SYNB-1020
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Umecrine Cognition AB
  • Spherium Biomed S.L.
  • Rebiotix Inc.
  • Ocera Therapeutics, Inc.
  • KannaLife Sciences, Inc.
  • Horizon Pharma Plc
  • Cosmo Pharmaceuticals S.p.A
  • Alfa Wassermann S.p.A

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hepatic Encephalopathy Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hepatic Encephalopathy Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Hepatic Encephalopathy Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Hepatic Encephalopathy Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Hepatic Encephalopathy Drug Market Dynamics
  1. 2.1 Hepatic Encephalopathy Drug Industry Trends
  2. 2.2 Hepatic Encephalopathy Drug Industry Drivers
  3. 2.3 Hepatic Encephalopathy Drug Industry Opportunities and Challenges
  4. 2.4 Hepatic Encephalopathy Drug Industry Restraints
3 Hepatic Encephalopathy Drug Market by Manufacturers
  1. 3.1 Global Hepatic Encephalopathy Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Hepatic Encephalopathy Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Hepatic Encephalopathy Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Hepatic Encephalopathy Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hepatic Encephalopathy Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Hepatic Encephalopathy Drug Manufacturers, Product Type & Application
  7. 3.7 Global Hepatic Encephalopathy Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hepatic Encephalopathy Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hepatic Encephalopathy Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hepatic Encephalopathy Drug Tier 1, Tier 2, and Tier 3
4 Hepatic Encephalopathy Drug Market by Type
  1. 4.1 Hepatic Encephalopathy Drug Type Introduction
  2. 4.1.1 GR-3027
  3. 4.1.2 KLS-13019
  4. 4.1.3 RBX-2660
  5. 4.1.4 SYNB-1020
  6. 4.1.5 Others
  7. 4.2 Global Hepatic Encephalopathy Drug Sales by Type
  8. 4.2.1 Global Hepatic Encephalopathy Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Hepatic Encephalopathy Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Hepatic Encephalopathy Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Hepatic Encephalopathy Drug Revenue by Type
  12. 4.3.1 Global Hepatic Encephalopathy Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Hepatic Encephalopathy Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2021-2032)
5 Hepatic Encephalopathy Drug Market by Application
  1. 5.1 Hepatic Encephalopathy Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Hepatic Encephalopathy Drug Sales by Application
  6. 5.2.1 Global Hepatic Encephalopathy Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatic Encephalopathy Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Hepatic Encephalopathy Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Hepatic Encephalopathy Drug Revenue by Application
  10. 5.3.1 Global Hepatic Encephalopathy Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hepatic Encephalopathy Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2021-2032)
6 Global Hepatic Encephalopathy Drug Sales by Region
  1. 6.1 Global Hepatic Encephalopathy Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatic Encephalopathy Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hepatic Encephalopathy Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Hepatic Encephalopathy Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hepatic Encephalopathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Hepatic Encephalopathy Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Hepatic Encephalopathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Hepatic Encephalopathy Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Hepatic Encephalopathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Hepatic Encephalopathy Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Hepatic Encephalopathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Hepatic Encephalopathy Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Hepatic Encephalopathy Drug Revenue by Region
  1. 7.1 Global Hepatic Encephalopathy Drug Revenue by Region
  2. 7.1.1 Global Hepatic Encephalopathy Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Hepatic Encephalopathy Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Hepatic Encephalopathy Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Hepatic Encephalopathy Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Hepatic Encephalopathy Drug Revenue (2021-2032)
  8. 7.2.2 North America Hepatic Encephalopathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Hepatic Encephalopathy Drug Revenue (2021-2032)
  11. 7.3.2 Europe Hepatic Encephalopathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Hepatic Encephalopathy Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Hepatic Encephalopathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Hepatic Encephalopathy Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Hepatic Encephalopathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Umecrine Cognition AB
  2. 8.1.1 Umecrine Cognition AB Company Information
  3. 8.1.2 Umecrine Cognition AB Business Overview
  4. 8.1.3 Umecrine Cognition AB Hepatic Encephalopathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Umecrine Cognition AB Hepatic Encephalopathy Drug Product Portfolio
  6. 8.1.5 Umecrine Cognition AB Recent Developments
  7. 8.2 Spherium Biomed S.L.
  8. 8.2.1 Spherium Biomed S.L. Company Information
  9. 8.2.2 Spherium Biomed S.L. Business Overview
  10. 8.2.3 Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Spherium Biomed S.L. Hepatic Encephalopathy Drug Product Portfolio
  12. 8.2.5 Spherium Biomed S.L. Recent Developments
  13. 8.3 Rebiotix Inc.
  14. 8.3.1 Rebiotix Inc. Company Information
  15. 8.3.2 Rebiotix Inc. Business Overview
  16. 8.3.3 Rebiotix Inc. Hepatic Encephalopathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Rebiotix Inc. Hepatic Encephalopathy Drug Product Portfolio
  18. 8.3.5 Rebiotix Inc. Recent Developments
  19. 8.4 Ocera Therapeutics, Inc.
  20. 8.4.1 Ocera Therapeutics, Inc. Company Information
  21. 8.4.2 Ocera Therapeutics, Inc. Business Overview
  22. 8.4.3 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product Portfolio
  24. 8.4.5 Ocera Therapeutics, Inc. Recent Developments
  25. 8.5 KannaLife Sciences, Inc.
  26. 8.5.1 KannaLife Sciences, Inc. Company Information
  27. 8.5.2 KannaLife Sciences, Inc. Business Overview
  28. 8.5.3 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product Portfolio
  30. 8.5.5 KannaLife Sciences, Inc. Recent Developments
  31. 8.6 Horizon Pharma Plc
  32. 8.6.1 Horizon Pharma Plc Company Information
  33. 8.6.2 Horizon Pharma Plc Business Overview
  34. 8.6.3 Horizon Pharma Plc Hepatic Encephalopathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Horizon Pharma Plc Hepatic Encephalopathy Drug Product Portfolio
  36. 8.6.5 Horizon Pharma Plc Recent Developments
  37. 8.7 Cosmo Pharmaceuticals S.p.A
  38. 8.7.1 Cosmo Pharmaceuticals S.p.A Company Information
  39. 8.7.2 Cosmo Pharmaceuticals S.p.A Business Overview
  40. 8.7.3 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product Portfolio
  42. 8.7.5 Cosmo Pharmaceuticals S.p.A Recent Developments
  43. 8.8 Alfa Wassermann S.p.A
  44. 8.8.1 Alfa Wassermann S.p.A Company Information
  45. 8.8.2 Alfa Wassermann S.p.A Business Overview
  46. 8.8.3 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product Portfolio
  48. 8.8.5 Alfa Wassermann S.p.A Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hepatic Encephalopathy Drug Value Chain Analysis
  2. 9.1.1 Hepatic Encephalopathy Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hepatic Encephalopathy Drug Production Mode & Process
  6. 9.2 Hepatic Encephalopathy Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hepatic Encephalopathy Drug Distributors
  9. 9.2.3 Hepatic Encephalopathy Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst